Novo Nordisk's Patent Cliff Looms as CFRA Downgrades and Pipeline Bets Accelerate

Novo Nordisk stock drops 25% in 2026 as CFRA downgrades to Sell; company counters with real-world data, Hengrui licensing deal and pipeline progress.

Investors in Novo Nordisk are pressing management for answers on two fronts: how much pricing power the Danish drugmaker can defend once exclusivity on semaglutide lapses, and whether its pipeline can plug the revenue gap. The market's verdict so far has been unforgiving. The stock has shed 25% since the start of the year and trades at EUR 33.10, roughly 40% below its 52-week high.

At the heart of the debate is the average revenue growth rate Novo Nordisk can sustain through 2030. Analysts expect a marked normalization in the back half of the decade, with annual growth settling into the mid-single digits as competition in obesity treatments intensifies. CFRA downgraded the company's US depositary receipts from Hold to Sell on 23 September, slapping a $38 price target on the shares. The research house cited an unfavorable risk-reward profile, mounting competitive pressure, and muted earnings growth in the years ahead, though it flagged Wegovy tablets as a near-term opportunity.

Sentiment had already soured before the downgrade. Following the company's capital markets day, the shares weakened noticeably as management's growth targets met with skepticism on the Street.

Real-World Data Arrive as a Counterweight

Against that cautious backdrop, Novo Nordisk has been busy stacking up clinical evidence. On 29 September, the company published a retrospective real-world analysis covering 636,525 adults with type-2 diabetes. Dose escalation of semaglutide was associated with a 6% lower risk of major cardiovascular events compared with switching to tirzepatide. The company acknowledges the methodology cannot establish causality, but the statistical comparison still offers tangible support for clinical practice — and, in the fight for market share, bolsters Novo's hand against rival treatment options. Cardiovascular comorbidities weigh heavily in therapy decisions for type-2 diabetics.

A day later, Novo released data from the OCTANE study showing that patients who switched from injectable therapies to the oral form of Wegovy lost an average of 4.1% of body weight over three months. The analysis draws on treatment data from telehealth platform Ro. Oral formulations represent a key strategic lever for the company, designed to lower the barrier to injection therapy and draw in new patient groups while broadening the therapeutic reach of its product family.

Licensing Deals and Label Expansions Fill the Gap

On the pipeline front, Novo signed an exclusive licensing agreement with Hengrui Pharma on 29 September for HRS-1596, an oral dual GLP-1/GIP agonist in Phase 1. The deal grants worldwide development, manufacturing, and commercialization rights excluding mainland China, Hong Kong, Macau, and Taiwan. The total financial package reaches up to $2.6 billion, including a $300 million upfront payment plus future milestone payments and revenue sharing. If such compounds can be steered swiftly through clinical trials, Novo could defend its technological leadership and establish new therapeutic approaches.

Additional relief may come from broader applications of already-approved products. Data released just over a week ago showed that Wegovy doses led to a normalization of liver fat content in patients with elevated levels, based on a subgroup analysis. Meanwhile, the company is targeting a US launch of Denecimig in the first half of 2027 following regulatory review of its application. The delay does not affect the financial forecast for the current fiscal year, according to the company.

The Bear Case: Eroding Pricing Power

In the pessimistic scenario, these initiatives arrive too late to offset fading pricing power. Should rival therapies reach the market faster or generic manufacturers force steep discounts after patent expiry, the earnings base wobbles. The metabolic disease market is increasingly turning into a battle for displacement, with payers demanding rebates. Regulatory requirements at existing manufacturing sites add another layer of risk: if Novo must commit substantial resources to remediating production facilities, those processes tie up capital and delay key product launches.

If follow-on products stall in approval processes or miss expectations for clinical superiority, a revaluation could push the shares further adrift from earlier peaks. Without credible answers to the looming margin squeeze, the stock's re-rating threatens to weigh on its valuation level permanently. Every percentage point of margin lost to price concessions must be offset by significantly higher sales volumes.

What to Watch Next

The medium-term trajectory now hinges on how robust the operating margin remains in the core segment. As long as Novo can hold sales volumes at a level that offsets pricing pressure and keep integration costs for acquisitions like the Hengrui deal in check, the company retains a viable foundation. But if pricing power on key products tips and margins compress faster than management anticipates, valuation pressure will intensify.

In pre-market trading on Tuesday, the stock showed stability at EUR 33.69, up 0.7% on the day, though still down 23% year-to-date. The next concrete catalyst is already circled: Novo Nordisk reports its next quarterly figures on 4 November, which will show just how resilient earnings prove to be in the ongoing competitive environment.